Life science lab definition and practical considerations for financing, underwriting, and risk management in CRE lending.
A life science lab is purpose-built space for biotech, pharmaceutical or diagnostic research that typically requires wet labs, stringent HVAC and air-change systems, backup power, biosafety measures and complex mechanical systems. In CRE lending, these assets demand thorough evaluation of tenant credit, grant funding stability, and the potential for specialized infrastructure to become stranded. Valuation considers high TI costs, long lease-up timelines and regional cluster strength. Lenders often require conservative LTVs, detailed technical reports, and contingency reserves to account for decommissioning and conversion expenses.
For financing life science labs, sponsors and brokers must present comprehensive engineering reports, evidence of tenant pipelines, and market demand from university and industry clusters. Lenders will scrutinize the tenant roster, revenue sources such as grants or licensing, and the amortization of tenant improvements. Finance professionals should model longer stabilization periods and higher capex reserves while proposing mitigants like phased funding or mezzanine layers. Demonstrating flexibility in lab layout and access to talent pools can materially improve lender appetite and loan terms.
Life science labs are high-capital, high-complexity assets whose specialized systems can drastically affect collateral recoverability and financing structures. Their success is closely linked to regional ecosystems, regulatory compliance, and tenant funding stability, so lenders must factor cluster risk and decommissioning costs into underwriting. Accurate risk allocation protects lenders from heavy losses if a tenant exits and the space cannot be repurposed quickly, while enabling sponsors to secure the appropriate capital to support costly build-outs for tenants driving innovation and potentially long-term, high-value leases.